Mpm Bioventures Iv Qp Lp - Net Worth and Insider Trading
Mpm Bioventures Iv Qp Lp Net Worth
The estimated net worth of Mpm Bioventures Iv Qp Lp is at least $74 Million dollars as of 2024-04-26. Mpm Bioventures Iv Qp Lp is the of Pacira BioSciences Inc and owns about 2,790,479 shares of Pacira BioSciences Inc (PCRX) stock worth over $74 Million. Mpm Bioventures Iv Qp Lp is also the 10% Owner of Conatus Pharmaceuticals Inc and owns about 1,192,080 shares of Conatus Pharmaceuticals Inc (CNAT) stock worth over $667,565. Details can be seen in Mpm Bioventures Iv Qp Lp's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Mpm Bioventures Iv Qp Lp has not made any transactions after 2013-07-30 and currently still holds the listed stock(s).
Transaction Summary of Mpm Bioventures Iv Qp Lp
Mpm Bioventures Iv Qp Lp Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mpm Bioventures Iv Qp Lp owns 6 companies in total, including Syndax Pharmaceuticals Inc (SNDX) , Chiasma Inc (CHMA) , and TriVascular Technologies Inc (TRIV) among others .
Click here to see the complete history of Mpm Bioventures Iv Qp Lp’s form 4 insider trades.
Insider Ownership Summary of Mpm Bioventures Iv Qp Lp
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| SNDX | Syndax Pharmaceuticals Inc | 2016-03-02 | 10 percent owner |
| CHMA | Chiasma Inc | 2015-07-21 | 10 percent owner |
| TRIV | TriVascular Technologies Inc | 2014-04-22 | 10 percent owner |
| EPZM | Epizyme Inc | 2013-05-30 | 10 percent owner |
| HSTO | Histogen Inc | 2013-07-24 | 10 percent owner |
| PCRX | Pacira BioSciences Inc | 2013-03-11 | 10 percent owner |
Mpm Bioventures Iv Qp Lp Latest Holdings Summary
Mpm Bioventures Iv Qp Lp currently owns a total of 2 stocks. Among these stocks, Mpm Bioventures Iv Qp Lp owns 2,790,479 shares of Pacira BioSciences Inc (PCRX) as of March 11, 2013, with a value of $74 Million and a weighting of 99.1%. Mpm Bioventures Iv Qp Lp also owns 1,192,080 shares of Conatus Pharmaceuticals Inc (CNAT) as of July 30, 2013, with a value of $667,565 and a weighting of 0.9%.
Latest Holdings of Mpm Bioventures Iv Qp Lp
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| PCRX | Pacira BioSciences Inc | 2013-03-11 | 2,790,479 | 26.34 | 73,501,217 |
| CNAT | Conatus Pharmaceuticals Inc | 2013-07-30 | 1,192,080 | 0.56 | 667,565 |
Holding Weightings of Mpm Bioventures Iv Qp Lp
Mpm Bioventures Iv Qp Lp Form 4 Trading Tracker
According to the SEC Form 4 filings, Mpm Bioventures Iv Qp Lp has made a total of 0 transactions in Pacira BioSciences Inc (PCRX) over the past 5 years. The most-recent trade in Pacira BioSciences Inc is the sale of 500,000 shares on March 11, 2013, which brought Mpm Bioventures Iv Qp Lp around $14 Million.
According to the SEC Form 4 filings, Mpm Bioventures Iv Qp Lp has made a total of 0 transactions in Conatus Pharmaceuticals Inc (CNAT) over the past 5 years. The most-recent trade in Conatus Pharmaceuticals Inc is the acquisition of 165,265 shares on July 30, 2013, which cost Mpm Bioventures Iv Qp Lp around $2 Million.
Insider Trading History of Mpm Bioventures Iv Qp Lp
- 1
Mpm Bioventures Iv Qp Lp Trading Performance
GuruFocus tracks the stock performance after each of Mpm Bioventures Iv Qp Lp's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mpm Bioventures Iv Qp Lp is 24.49%. GuruFocus also compares Mpm Bioventures Iv Qp Lp's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mpm Bioventures Iv Qp Lp within 3 months outperforms 2 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Mpm Bioventures Iv Qp Lp's insider trading performs compared to the benchmark.
Performance of Mpm Bioventures Iv Qp Lp
Average Return
62.67%
Outperforming Transactions
75%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 4.56 | 24.49 | 35.13 | 62.67 | 90.14 | 80.88 |
| Relative Return to S&P 500(%) | 4.04 | 19.25 | 33.85 | 50.74 | 75.91 | 67.23 |
Mpm Bioventures Iv Qp Lp Ownership Network
Ownership Network List of Mpm Bioventures Iv Qp Lp
Ownership Network Relation of Mpm Bioventures Iv Qp Lp
Mpm Bioventures Iv Qp Lp Owned Company Details
What does Syndax Pharmaceuticals Inc do?
Who are the key executives at Syndax Pharmaceuticals Inc?
Mpm Bioventures Iv Qp Lp is the 10 percent owner of Syndax Pharmaceuticals Inc. Other key executives at Syndax Pharmaceuticals Inc include director & Chief Executive Officer Briggs Morrison , Chief Financial Officer Keith A. Goldan , and President & Head of R&D Neil Gallagher .
Syndax Pharmaceuticals Inc (SNDX) Insider Trades Summary
Over the past 18 months, Mpm Bioventures Iv Qp Lp made no insider transaction in Syndax Pharmaceuticals Inc (SNDX). Other recent insider transactions involving Syndax Pharmaceuticals Inc (SNDX) include a net sale of 369,983 shares made by Briggs Morrison , a net sale of 50,069 shares made by Peter Ordentlich , and a net sale of 83,000 shares made by William Meury .
In summary, during the past 3 months, insiders sold 0 shares of Syndax Pharmaceuticals Inc (SNDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 548,588 shares of Syndax Pharmaceuticals Inc (SNDX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 548,588 shares.
Syndax Pharmaceuticals Inc (SNDX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Syndax Pharmaceuticals Inc Insider Transactions
Mpm Bioventures Iv Qp Lp Mailing Address
Above is the net worth, insider trading, and ownership report for Mpm Bioventures Iv Qp Lp. You might contact Mpm Bioventures Iv Qp Lp via mailing address: 200 Clarendon Street, 54th Floor, Boston Ma 02116.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
